Highlights on CLL and Richter syndrome

MediMix is pleased to share a summary of the informative session on CLL and Richter syndrome, kindly provided by Prof. Ann Janssens, a hematologist at UZ Leuven.

Prof. Janssens discusses the findings of the Phase 3 CLL12 trial, which evaluated the effectiveness of ibrutinib in patients with early-stage CLL at an increased risk of progression. She also presented the long-term outcomes of the CLL14 study, which focused on patients with previously untreated CLL, up to a six-year period.

Additionally, Prof Janssens highlighted three studies that addressed an unmet medical need in patients with CLL and Richter syndrome. 

With the educational support of: